Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Completed · Phase 3 · Has a placebo group
Conditions studied: Glabellar Frown Lines
In brief
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Key facts
- Study ID
- NCT03960957
- Run by
- Galderma R&D
- People needed
- 301
- Starts
- 2019-06-17
- Expected to finish
- 2020-04-16
- Last updated by the study team
- 2022-08-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Moderate to severe glabellar lines at maximum frown
- Understands the study requirements and signs an informed consent form
You may not qualify if…
- Botulinum toxin treatment in the face within 6 months prior to study treatment
Where it is running
- Galderma Study Site — Redondo Beach, California, United States
- Galderma Study Site — San Diego, California, United States
- Galderma Study Site — Westport, Connecticut, United States
- Galderma Study Site — Washington D.C., District of Columbia, United States
- Galderma Study Site — Coral Gables, Florida, United States
- Galderma Study Site — Atlanta, Georgia, United States
- Galderma Study Site — St Louis, Missouri, United States
- Galderma Study Site — Omaha, Nebraska, United States
- Galderma Study Site — Cincinnati, Ohio, United States
- Galderma Study Site — Austin, Texas, United States
- Galderma Study Site — Spring, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.